Introduction
Vitamin D is a fat-soluble secosteroid that can be ingested or derived endogenously through exposure of the skin to the ultraviolet spectrum in sunlight [1] . With a reported half-life of approximately 3 weeks, 25-hydroxyvitamin D [25(OH)D] is the main circulating metabolite of vitamin D and the best measurement of overall vitamin D status [1] . Low vitamin D status has been implicated in the occurrence of rickets, cell differentiation, cell growth, metabolism and immunity [2] .
The US Institute of Medicine suggests that achieving 25(OH)D levels of at least 30 nmol/L will prevent deficiency with respect to bone health and 50 nmol/L will ensure sufficiency in practically all individuals [1] .
Different cut points are used by other groups; for example, the Endocrine Society uses \50, 50 to \75 and C75 nmol/ L to define deficiency, insufficiency, and sufficiency, respectively [3] . Among Canadian women aged 20-39 years, 63.7 % are estimated to have 25(OH)D levels below 75 nmol/L and 25.5 % are estimated to have levels below 50 nmol/L [4, 5] .
The vitamin D status that is optimal for neonatal outcomes is unknown since inconsistent results have been observed among studies (reviewed in [6] ). Most evidence about the association between vitamin D status and neonatal outcomes comes from studies in which maternal vitamin D status was determined in early to mid-pregnancy [6] [7] [8] . Fewer studies have examined vitamin D status later in pregnancy, a time window when the immunological and metabolic effects of vitamin D may be more likely to have an impact on neonatal outcomes such as premature birth and birthweight [9] [10] [11] [12] [13] [14] . The sample sizes in the studies that have examined vitamin D status later in pregnancy have been small. Furthermore, the analyses have been mostly limited to the examination of birthweight or gestational age in their continuous form rather than in the clinically relevant categories of low birthweight (LBW), small for gestational age (SGA), and preterm birth (PTB). These outcomes are of considerable importance because of the increased risk of mortality and short-and long-term morbidity associated with them [15] [16] [17] . Therefore, this study was conducted to determine whether vitamin D status in cord blood, as measured by level of 25(OH)D, is associated with LBW, SGA, and PTB.
Materials and methods
A nested case-control study was conducted within a cohort of women recruited in pregnancy at the Centre Hospitalier Universitaire (CHU) de Québec in Quebec City, Canada. Women who presented for their first routine prenatal visit or at the dating ultrasound (2008-10) were enrolled. At a subsequent visit, participants filled out a questionnaire about their demographic characteristics, reproductive history, and lifestyle. A blood sample was taken from the umbilical cord at delivery and medical charts were reviewed after delivery. Of the women who were approached to participate in the cohort study, 85 % agreed and provided informed consent, for a total of 7929 women. Fifty-five participants withdrew from the study.
Research Ethics Board approval was received from the IWK Health Centre in Halifax, the CHU de Québec in Quebec City, and McGill University in Montreal for conducting 25(OH)D analyses on the stored blood samples from the cohort participants.
Only live born singletons were included in the present study. Cases were defined by LBW infant, SGA infant, and/or PTB: (1) a LBW infant was one weighing \2500 g at birth; (2) a SGA infant was one born below the 10th percentile based on Canadian standards for sex-specific birthweight by gestational week [18] ; and (3) PTB was a delivery occurring at \37 weeks' gestation, with gestational age based on ultrasound information, if available, or else the last menstrual period. Controls were frequency matched to all of the cases from the cohort based on gestational week of enrollment and season and year of the maternal blood sample collected at the time of recruitment.
Cord blood samples were processed immediately, and serum aliquots were stored at -80°C until they were shipped on dry ice to McGill University for measurement. Concentrations of 25(OH)D were determined using an automated chemiluminesence immunoassay (DiaSorin Liaison, Stillwater, MN, USA) without knowledge of casecontrol status. The laboratory received a Certificate of Proficiency for 2009-2010 from the Vitamin D External Quality Assessment Scheme (DEQAS) indicating that at least 80 % of the reported results were no more than 30 % outside of the all-laboratory trimmed mean (ALTM). Internal quality control measures included duplicate measures of high and low controls supplied in the manufacturer kits, and a pooled serum sample from nonpregnant healthy adults. The laboratory also received a quality assurance certified value from the National Institute for Standards and Technology (NIST). Accuracy using NIST 25(OH)D controls indicated a 3.3 % difference of the ALTM from the NIST reference measurement procedure in October 2012 and a 6.3 % difference in January 2013. The inter-assay coefficient of variation (CV) was 5.7 % and the range of intra-assay CVs was 1.4-7.6 % with a mean of 3.9 % across runs.
Factors that were considered as potential confounders were based on the current literature and biological plausibility and included: maternal age (\25, 25-29, 30-34, and C35 years), parity (primiparous, multiparous), annual household income (\25,000, 25,000-39,999, 40,000-59,999, C60,000 Canadian dollars), education [high school or less, college (CEGEP), university], relationship status (married or common law, other), ethnicity (Caucasian, other), prepregnancy body mass index (\25, 25 to \30, C30 kg/m 2 ), maternal smoking during pregnancy (no, yes), physical activity for 20-30 min before pregnancy (none, 1-3 times/month, C1 times/week), gestational diabetes (no, yes), pre-eclampsia (no, yes), season of cord blood sample measurement (February-April, MayJuly, August-October, November-January), and infant sex.
Potential confounders were compared between the cases and controls using Mann-Whitney tests for continuous variables and Fisher's exact tests for categorical variables.
Vitamin D status was classified as \50, 50 to \75, and C75 nmol/L. We were unable to include a group with lower levels due to small numbers [e.g., only 5 % in the study sample had 25(OH)D \30 nmol/L]. The crude associations between vitamin D status (each level compared to the referent of C75 nmol/L) and PTB, LBW, and SGA outcomes were determined separately using logistic regression to estimate odds ratios (OR) and 95 % confidence intervals (CI). Potential confounders were assessed for their effect on the association between 25(OH)D and each neonatal outcome. In other words, potential confounders that resulted in at least a 5 % difference between the adjusted OR and crude OR were included in the adjusted models. A sensitivity analysis for the PTB outcome was conducted to explore the effect of excluding neonates born at \34 weeks' gestation. To better describe the relationships across the continuum of 25(OH)D, a post hoc logistic regression analysis using restricted cubic splines with knots at 30, 65 and 110 nmol/L was done and the natural log (ln) of the adjusted OR with 95 % confidence intervals shown graphically. All statistical analyses were performed in SAS 9.2 (Cary, NC). The significance for all tests was set at a p value \0.05.
Results
Key participant characteristics, by case-control status, are displayed in Table 1 . Among controls, 47.4 % of women were 30 years of age or more, 14.0 % were obese, and 73.4 % participated in leisure-time physical activity lasting 20-30 min at least two times per week. Parity, income, smoking, BMI, physical activity, pre-eclampsia, and infant sex were associated with at least one of the three outcomes under study. Within cord blood samples, the distribution of 25(OH)D concentration in controls (median 64.5 nmol/L) was significantly lower than in the LBW cases (median 71.7 nmol/L, p = 0.02) but similar to the SGA cases (median 63.6 nmol/L, p = 0.97) and the PTB cases (median 67.1 nmol/L, p = 0.09).
Crude and adjusted ORs for the association between cord blood 25(OH)D concentration and the neonatal outcomes are shown in Table 2 The graphs of the relative odds of these outcomes across the continuum of 25(OH)D modeled using restricted cubic splines reflects the results derived from analyses with 25(OH)D concentrations represented in categories (Fig. 1) . The inverse association between 25(OH)D concentration and LBW was observed across the range of 25(OH)D, whereas the association with SGA tended toward a U-shape with the odds increased at both low and high levels of 25(OH)D. The confidence intervals, however, were wide at the extremes of the range of 25(OH)D.
Discussion
This study set out to determine whether vitamin D status as assessed by 25(OH)D concentration in cord blood was associated with LBW, SGA, and PTB in a birth cohort from Quebec City, Canada. Compared to 25(OH)D concentrations C75 nmol/L, concentrations of \50 nmol/L were associated with lower odds of LBW, though with only 13 cases of LBW with 25(OH)D concentrations \50 nmol/ L, our estimates lacked precision. In adjusted analyses, no significant associations were observed with SGA or PTB.
In another Canadian study, Weiler et al. [14] produced findings similar to the present study with regard to birthweight, finding that mean birthweight was 299 g lower in 32 neonates with cord blood 25(OH)D levels above 37.5 nmol/L relative to 18 neonates with levels below 37.5 nmol/L (p = 0.02). In a distinct setting (Pakistan), Hossain et al. [12] also observed a significant inverse correlation between cord blood 25(OH)D concentration and birthweight. In contrast, Bowyer et al. [9] found no significant difference in mean birthweight among neonates with cord blood 25(OH)D concentrations below versus above 25 nmol/L. Overall, examinations of neonatal or maternal 25(OH)D level at delivery or the proximal postpartum period in relation to birthweight have shown heterogeneous results, whereas all studies but one of maternal vitamin D status earlier in gestation have found no association with birthweight (reviewed in [6] ). Recent randomized trials have also found no effect of vitamin D supplementation on birthweight [19, 20] .
In contrast to our finding of a null association between 25(OH)D level and the risk of SGA, Burris et al. [10] reported an OR of 4.64 (95 % CI 1.61-13.36) for SGA among neonates with cord blood 25(OH)D concentrations \25 versus C25 nmol/L. If in the present study we had been able to include a sufficiently sized group with levels \25 nmol/L, we may have seen an effect. Of note, similar to the results of our exploratory analyses with cubic splines, another observational study of maternal vitamin D 
Data are presented as n (%) unless otherwise indicated a p value from Fisher's exact test for the difference in proportions between this case group and controls, excluding participants with missing values b p value from Mann-Whitney test comparing this case group and controls [21] . Two recent meta-analyses that examined the relationship between maternal vitamin D status in early to mid-gestation and SGA found increased summary ORs for 25(OH)D levels\50 nmol/L but no difference based on levels \75 nmol/L [7, 8] .
For comparison to our finding of a nonsignificant association between higher 25(OH)D level and PTB, Hossain et al. [12] found that higher cord blood vitamin D status was significantly associated with shorter gestational periods. Three other studies examining cord blood found no significant association between lower 25(OH)D and risk of PTB [11, 13, 22] . In contrast to the studies that have examined cord blood, a recent meta-analysis of four observational studies that examined maternal mid-gestation vitamin D status revealed an OR of 1.58 (95 % CI 1.08-2.31) for PTB for 25(OH)D \50 nmol/L relative to C50 nmol/L [8] . Moderate heterogeneity among the studies was observed, however, with three studies showing null findings and one large study showing a significant positive association [8] . In addition, recent large randomized trials have found no difference in gestational age at birth among different supplementation groups despite significant differences in the prevalence of 25(OH)D C50 nmol/L in cord blood [19, 20] . Although the effect of vitamin D on immune function and inflammatory response [2] provides a plausible mechanism for reduction in risk of PTB, the human evidence is heterogeneous.
It is important to note the possibility of reverse causality in the relationship between cord blood vitamin D status and adverse neonatal outcomes. For example, a decline in maternal vitamin D status across pregnancy or in the third trimester has been observed [23] [24] [25] ; potential explanations for this decline could be that fetal demand increases with growth [23] or that vitamin D gets sequestered in the growing depot of fetal adipose tissue. Given that maternal and fetal 25(OH)D concentrations are highly correlated [9] , this decline could explain our finding of lower odds of LBW with cord blood 25(OH)D concentrations of \50 nmol/L compared to C75 nmol/L. Other human evidence, however, suggests that vitamin D levels may increase across gestation with maternal supplement use [26] or may remain steady [27] .
One limitation of this study is that a greater proportion of cases were missing cord blood samples than controls (39.8 versus 27.5 %). It is likely that more cord blood samples were missing among especially unhealthy babies because the birth team would have prioritized urgent treatment over the collection of cord blood for research purposes. If the risk associated with vitamin D status shows a gradation with neonatal outcomes of increasing severity, differences between cases and controls could have been attenuated. However, the congruency of our study population with the literature on maternal smoking, physical activity, and risk of adverse neonatal outcomes [28] [29] [30] suggests that selection bias did not strongly affect the results.
The strengths of the present study include using cord blood as a potentially more direct measure of fetal vitamin D status. Our large sample size enabled us to examine two higher categories of vitamin D status with adequate Fig. 1 The dose-response relationship between cord 25(OH)D concentration, relative to 75 nmol/L, and the odds of LBW (a), SGA (b), and PTB (c); solid lines represent the point estimate and the dashed lines represent the 95 % confidence intervals derived from adjusted logistic regression models using restricted cubic splines statistical power although we acknowledge that we were unable to examine the odds associated with 25(OH)D concentrations below 50 nmol/L with much precision. Our results are unlikely to be confounded by ethnicity since our cohort comprised 97 % Caucasian women.
The results of this study suggest that cord blood concentrations of 25(OH)D are not associated with PTB or SGA and that 25(OH)D concentrations \50 nmol/L compared to concentrations C75 nmol/L may be associated with lower odds of LBW. Even so, replication of these results will be needed in larger study populations and prenatal vitamin D recommendations will require an examination of the literature at large with consideration of the full spectrum of maternal and neonatal outcomes. Nevertheless, given the significant impact of adverse neonatal outcomes in the short-term and throughout the life-course, further investigation of the relationship between neonatal vitamin D status and the risk of adverse neonatal outcomes is required.
